TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive NCI Plans Program To Help Academics With Initial Stages of Drug Discovery. November 30, 2007
TCL Archive Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials. October 15, 2004
TCL Archive NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say. April 16, 2004
